Search clinical trials for: Relapsed/refractory Myeloma

Total 3802 results

Ichnos Sciences SA

Recruiting

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

United States, Australia
GlaxoSmithKline

Active, not recruiting

Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (DREAMM 7)

Multiple Myeloma

Australia, Japan, Spain, Germany, Poland, Belgium, Israel, Italy, Russian Federation, Canada, New Zealand, Korea, Republic of, China, Brazil, Czechia, United States, Netherlands, United Kingdom, Greece, France
Oncotherapeutics
Takeda

Completed

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Multiple Myeloma

United States
AbbVie
Genentech, Inc.

Completed

A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy (Bellini)

Relapsed/Refractory Multiple Myeloma

United States, Australia, Brazil, Canada, France, Germany, Hungary, Ireland, Italy, Japan, Korea, Republic of, Russian Federation, Spain, Taiwan, Ukraine, United Kingdom
AbbVie
Genentech, Inc.

Completed

Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

United States, Belgium, France, Norway
Karyopharm Therapeutics Inc

Withdrawn

Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients (SLAM)

Multiple Myeloma
Celularity Incorporated

Completed

A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)

Multiple Myeloma

United States
Alaunos Therapeutics

Completed

A Phase I Trial of ZIO-101 in Hematologic Cancers

Lymphoma | Multiple Myeloma | Acute Leukemia | Chronic Myeloproliferative Disease | Chronic Lymphoproliferative Disease | Poor-risk Myelodysplasia (MDS)

United States
University Health Network, Toronto
Myeloma Canada; The Leukemia and Lymphoma Society of Canada

Not yet recruiting

Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma

Lymphoma, B-Cell | Multiple Myeloma | B Cell Lymphoma | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Multiple Myeloma Progression | Multiple Myeloma Stage III | Aggressive Lymphoma
Brigham and Women's Hospital
Medical University of South Carolina; M.D. Anderson Cancer Center; Massachusetts... and other collaborators

Recruiting

Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy

Multiple Myeloma | Acute Kidney Injury | Light Chain Nephropathy

United States
Washington University School of Medicine
Pfizer; National Comprehensive Cancer Network; Rapid Novor

Not yet recruiting

Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance Using Peripheral Blood Clonotypic Mass Spectrometry

Multiple Myeloma

United States
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Clinical Study of SHR-9539 in Patients With Multiple Myeloma

Multiple Myeloma

China
Chengdu Zenitar Biomedical Technology Co., Ltd

Not yet recruiting

Puesta Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma (RRMM)

China
University Medical Center Groningen

Not yet recruiting

Bleeding in Multiple Myeloma (BiMM)

Multiple Myeloma
Pfizer

Not yet recruiting

Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.

Relapsed and Refractory Multiple Myeloma (RRMM)
Universitaire Ziekenhuizen KU Leuven
Janssen Pharmaceutica

Not yet recruiting

Study on the Clinical Efficacy of Teclistamab (TECTONIC)

Hematologic Diseases | Multiple Myeloma

Belgium
The First Affiliated Hospital with Nanjing Medical...
Nanjing Legend Biotech Co.

Not yet recruiting

LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

China
Centre Hospitalier Universitaire de Saint Etienne

Not yet recruiting

Comparison of the Effects of Apixaban on Thrombin Generation in Patients With de Novo Multiple Myeloma (ProApix)

Multiple Myeloma | Total Knee Replacement

France
Janssen-Cilag Ltd.

Recruiting

A Real-world Study in Participants With Smoldering Multiple Myeloma

Smoldering Multiple Myeloma

France
First Affiliated Hospital of Zhejiang University
First Affiliated Hospital of Wenzhou Medical University; The Affiliated Hospital... and other collaborators

Recruiting

Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not

Multiple Myeloma | Minimal Residual Disease

China
Nanjing IASO Biotechnology Co., Ltd.

Recruiting

A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03) (FUMANBA-03)

Multiple Myeloma

China
National Cancer Institute (NCI)

Not yet recruiting

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Hard-to-Treat Multiple Myeloma

Multiple Myeloma
Stanford University
Janssen, LP

Not yet recruiting

Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma

Multiple Myeloma | Post Stem Cell Transplant

United States
Assiut University

Not yet recruiting

Clinical Outcomes and Prognostic Factors in Multiple Myeloma Patients

Multiple Myeloma
Durham VA Medical Center
Duke University

Not yet recruiting

Telehealth-based Symptom Management for Veterans Treated With Selinexor (Selinexor)

Multiple Myeloma | Large-cell Lymphoma
University of Leeds
The Leeds Teaching Hospitals NHS Trust

Not yet recruiting

PROSpECT-PRIOR-2-CHEMO: PRIOR Dental Intervention Before Chemo to Reduce Chemotherapy Complications

Periodontitis | Febrile Neutropenia | Oncology | Myeloma | Oral Mucositis

United Kingdom
Changchun GeneScience Pharmaceutical Co., Ltd.

Not yet recruiting

Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.

Breast Cancer Subjects

China
InSilico Medicine Hong Kong Limited

Recruiting

Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma

Advanced Solid Tumors | Relapsed/Refractory B-cell Lymphoma

China
Opna Bio LLC

Recruiting

Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Refractory Multiple Myeloma | Relapsed Multiple Myeloma

United States
Shenzhen Geno-Immune Medical Institute
The No.2 Clinical Hospital of the Ministry of Health

Recruiting

Engineered Dendritic Cell Vaccines for Multiple Myeloma

Multiple Myeloma or Plasmacytoma

China, Russian Federation
Insel Gruppe AG, University Hospital Bern

Not yet recruiting

PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab) (PRONTO)

Lymphoma | Leukemia | Myeloma

Switzerland
Shenzhen Geno-Immune Medical Institute
The No.2 Clinical Hospital of the Ministry of Health

Recruiting

Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma

Multiple Myeloma | Plasmacytoma

China, Russian Federation
Janssen Research & Development, LLC

Recruiting

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-10)

Relapsed or Refractory Multiple Myeloma

Korea, Republic of, United States, Australia
Ontario Clinical Oncology Group (OCOG)
Pfizer

Not yet recruiting

Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma (EMBRACE)

Refractory Multiple Myeloma

Canada
Nantes University Hospital

Not yet recruiting

Evaluation of a Range of Dermo-cosmetic Products to Treat Skin and Nail Toxicity Linked to Bispecific Anti-GPRC5D Bispecific Antibodies in Multiple Myeloma Patients". Myeloma". Descriptive Pilot Study (DELICATESSE)

Myeloma Multiple
Kite, A Gilead Company
Arcellx, Inc.

Not yet recruiting

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (iMMagine-3)

Multiple Myeloma
Jules Bordet Institute
RayzeBio, Inc.

Not yet recruiting

A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors (AcTRESS)

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Multiple Myeloma Progression

Belgium
The First Affiliated Hospital of Soochow University

Not yet recruiting

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

Multiple Myeloma | Newly Diagnosed | MRD | High Risk
University Hospital, Angers

Not yet recruiting

Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation. (ALHERT)

Lymphoma | Leukemia | Multiple Myeloma

France
Shanghai Changzheng Hospital
CARsgen Therapeutics Co., Ltd.

Recruiting

Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma

Multiple Myeloma

China
Celgene
Bristol-Myers Squibb

Recruiting

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)

Multiple Myeloma

Austria, United States, Spain, Australia, Japan, France, Israel, Italy, Canada, Greece, Belgium, Norway, Romania, Czechia, Denmark, Germany, Korea, Republic of, United Kingdom, Poland
Sidney Kimmel Comprehensive Cancer Center at Johns...
Janssen Research & Development, LLC

Not yet recruiting

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

Lymphoma | Multiple Myeloma | Hodgkin Lymphoma | Myelofibrosis | Non Hodgkin Lymphoma | Chronic Myeloid Leukemia | Hematologic Malignancy | Aplastic Anemia | Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML) | Bone Marrow Transplant Rejection | Acute Lymphoblastic Leukemia (ALL), Adult
Peking University First Hospital

Recruiting

PET Imaging Study of 68Ga-NB381 in Multiple Myeloma

Multiple Myeloma

China
IRCCS Policlinico S. Matteo

Recruiting

Promoting Diagnosis and Management of AL in Italy (ProDigALIty) (ProDigALIty)

AL Amyloidosis | Monoclonal Gammopathy of Undetermined Significance | Smoldering Multiple Myeloma

Italy
Cullinan Therapeutics Inc.

Not yet recruiting

A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma
Changzhou No.2 People's Hospital

Not yet recruiting

An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma

Multiple Myeloma

China
Dickran Kazandjian, MD
Regeneron Pharmaceuticals

Not yet recruiting

IMMUNOPLANT for Newly Diagnosed Multiple Myeloma (IMMUNOPLANT)

Multiple Myeloma

United States
Jiangsu Simcere Pharmaceutical Co., Ltd.
Shanghai Xianxiang Medical Technology Co., Ltd.

Recruiting

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

China
Peking University People's Hospital

Not yet recruiting

A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.

Relapsed/Refractory Multiple Myeloma

China
Tufts Medical Center
National Cancer Institute (NCI)

Not yet recruiting

Screening for AL Amyloidosis in Smoldering Multiple Myeloma

Smoldering Multiple Myeloma

United States

Search clinical trials for: Relapsed/refractory Myeloma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations